VELCADE Side Effects

6911762-3 | Dehydration, Hypoxia, Muscular Weakness, Pneumonia, Pneumonitis Chemical, Respiratory Failure, Respiratory Tract Infection Fungal
on Jul 26, 2010 Male patient from UNITED STATES , weighting 208.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, hypoxia, muscular weakness, pneumonia (What is pneumonia?), pneumonitis chemical, respiratory failure, respiratory tract infection fungal. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with DOXIL (30 Mg/m2, Cyclic) (View Doxil Review and Doxil Label ), DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), CYCLOPHOSPHAMIDE (750 Mg/m2, Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ), ACYCLOVIR (400 Mg, Bid) (View Acyclovir Review and Acyclovir Label ), ASPIRIN (81 Mg, Qd) (View Aspirin Review and Aspirin Label ), COLACE (100 Mg, Bid) (View Colace Review and Colace Label ), OXYCONTIN (10 Mg, Bid) (View Oxycontin Review and Oxycontin Label ), PAXIL (40 Mg, Qd) (View Paxil Review and Paxil Label ). Patient was hospitalized.

6909307-7 |
Patient was taking Velcade (View Usage). on Aug 02, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 128.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), THALIDOMIDE (100 Mg, Cyclic) (View Thalidomide Review and Thalidomide Label ).

6909076-0 | Osteonecrosis
Adverse event was reported on Jul 26, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 1.3 Mg/m2, Cyclic) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: UNITED STATES , 67 years of age, weighting 200.6 lb, After Velcade was administered, patient had the following side effects: osteonecrosis (What is osteonecrosis?). During the same period patient was treated with REVLIMID (25 Mg, Cyclic) (View Revlimid Review and Revlimid Label ), DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), ASPIRIN (325 Mg, Qd) (View Aspirin Review and Aspirin Label ), ZOMETA (View Zometa Review and Zometa Label ).

6907935-6 | Abdominal Pain, Myopericarditis, Renal Failure Acute
on Jul 27, 2010 Female patient from UNITED STATES , weighting 112.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), prophylaxis of nausea and vomiting and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), myopericarditis, renal failure acute. Velcade dosage: 1 Mg/m2, Cyclic. During the same period patient was treated with REVLIMID (10 Mg, Unk) (View Revlimid Review and Revlimid Label ), DECADRON (10 Mg, Unk) (View Decadron Review and Decadron Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), LORAZEPAM (0.5 Mg, Prn) (View Lorazepam Review and Lorazepam Label ), NEPHROCAPS (View Nephrocaps Review and Nephrocaps Label ), ANZEMET (100 Mg, Unk) (View Anzemet Review and Anzemet Label ). Patient was hospitalized and became disabled.


6907925-3 | Acute Leukaemia
on Jul 26, 2010 Male patient from UNITED STATES , weighting 160.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient had the following side effects: acute leukaemia. Velcade dosage: 2.3 Mg, Unk. During the same period patient was treated with ZOFRAN (View Zofran Review and Zofran Label ), DEXAMETHASONE (20 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), ZOMETA (4 Mg, Unk) (View Zometa Review and Zometa Label ), GLIPIZIDE (2.5 Mg, Qd) (View Glipizide Review and Glipizide Label ). Patient was hospitalized.

6900630-9 | Amnestic Disorder, Aphasia, Cognitive Disorder, Dementia, Memory Impairment, Speech Disorder
Patient was taking Velcade (View Usage). After Velcade was administered, patient had the following side effects: amnestic disorder, aphasia (What is aphasia?), cognitive disorder, dementia (What is dementia?), memory impairment, speech disorder on Jul 21, 2010 from GERMANY Additional patient health information: Female patient , 54 years of age, weighting 132.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 2.1 Mg, Intravenous 1.7, Intravenous. During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ).

6900456-6 | West Nile Viral Infection
Adverse event was reported on Jul 30, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 1.3 Mg/m2, Cyclic) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , weighting 156.5 lb, Patient experienced the following unwanted or unexpected effects: west nile viral infection. During the same period patient was treated with CYCLOPHOSPHAMIDE (600 Mg, Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ), DEXAMETHASONE (40 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), RITUXIMAB (375 Mg/m2, Cyclic) (View Rituximab Review and Rituximab Label ), ACYCLOVIR (400 Mg, Bid) (View Acyclovir Review and Acyclovir Label ), LEVOTHYROXINE SODIUM (125 Mg, Qd) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), LORAZEPAM (1 Mg, Prn) (View Lorazepam Review and Lorazepam Label ). Patient was hospitalized.

6895810-5 | Acute Respiratory Distress Syndrome, Fungaemia, Mental Impairment, Multi-organ Failure, Pneumonia, Sepsis
on Jul 23, 2010 Female patient from UNITED STATES , 64 years of age, was diagnosed with leukaemia plasmacytic and was treated with Velcade (View Usage). Patient had the following side effects: acute respiratory distress syndrome, fungaemia, mental impairment, multi-organ failure, pneumonia (What is pneumonia?), sepsis (What is sepsis?). Velcade dosage: . Patient was hospitalized.

6895802-6 | Acute Myeloid Leukaemia
on Jul 23, 2010 Male patient from UNITED STATES , 59 years of age, was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: acute myeloid leukaemia. Velcade dosage: Unk. During the same period patient was treated with MELPHALAN (View Melphalan Review and Melphalan Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6895759-8 | Acute Graft Versus Host Disease In Intestine, Colitis, Cytomegalovirus Gastroenteritis, Duodenitis, Enterocolitis, Erythema, Gastritis, Gastritis Erosive, Gastrointestinal Disorder
Patient was taking Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, colitis, cytomegalovirus gastroenteritis, duodenitis, enterocolitis, erythema, gastritis, gastritis erosive, gastrointestinal disorder on Jul 23, 2010 from UNITED STATES Additional patient health information: Male patient , 49 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 1.0 Mg/m2, Cyclic. During the same period patient was treated with DEXAMETHASONE (40 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), THALIDOMIDE (200 Mg, Cyclic) (View Thalidomide Review and Thalidomide Label ), DOXORUBICIN HCL (10 Mg/m2, Cyclic) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (400 Mg/m2, Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6883793-3 | Dehydration, Hyponatraemia, Hypophosphataemia, Pyrexia, Renal Failure Acute, Rhabdomyolysis
Adverse event was reported on Jul 16, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 2.7 Mg, Unk) was diagnosed with multiple myeloma (What is multiple myeloma?), diabetes mellitus and. Location: UNITED STATES , weighting 213.0 lb, Patient had the following side effects: dehydration, hyponatraemia, hypophosphataemia, pyrexia, renal failure acute, rhabdomyolysis. During the same period patient was treated with ZOMETA (3.5 Mg, Q4weeks) (View Zometa Review and Zometa Label ), REVLIMID (View Revlimid Review and Revlimid Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), INSULIN (View Insulin Review and Insulin Label ), ZOSYN (View Zosyn Review and Zosyn Label ), COLACE (View Colace Review and Colace Label ), LOVENOX (View Lovenox Review and Lovenox Label ), NEURONTIN (View Neurontin Review and Neurontin Label ). Patient was hospitalized.

6883513-2 | H1n1 Influenza, Hyponatraemia, Hypoxia, Oral Candidiasis, Pneumonia
on Jul 19, 2010 Male patient from UNITED KINGDOM , 67 years of age, weighting 152.6 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: h1n1 influenza, hyponatraemia, hypoxia, oral candidiasis, pneumonia (What is pneumonia?). Velcade dosage: 2.2 Mg, Cyclic, Intravenous. During the same period patient was treated with DOXORUBICIN HCL (60 Mg, Cyclic, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40 Mg, Oral) (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

6883401-1 | Cardiac Failure Congestive, Cardiomyopathy, Left Ventricular Dysfunction
on Jul 21, 2010 Female patient from UNITED STATES , weighting 140.5 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure congestive, cardiomyopathy (What is cardiomyopathy?), left ventricular dysfunction. Velcade dosage: 1.6 Mg/m2, Cyclic. During the same period patient was treated with THALIDOMIDE (100 Mg, Cyclic) (View Thalidomide Review and Thalidomide Label ), DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), CARVEDILOL (12.5 Mg, Bid) (View Carvedilol Review and Carvedilol Label ), ALDACTONE (25 Mg, Bid) (View Aldactone Review and Aldactone Label ), ZOMETA (View Zometa Review and Zometa Label ), ELAVIL (Unk) (View Elavil Review and Elavil Label ), ZOFRAN (Unk) (View Zofran Review and Zofran Label ), LASIX (20 Mg, Qd) (View Lasix Review and Lasix Label ). Patient was hospitalized.

6883136-5 | Atrial Fibrillation, Confusional State, Renal Failure, Skin Exfoliation
Patient was taking Velcade (View Usage). Patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), confusional state, renal failure, skin exfoliation on Jul 22, 2010 from UNITED STATES Additional patient health information: Male patient , 79 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 2.5 Mg, 1/week. During the same period patient was treated with IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (Unk) (View Immune Globulin Intravenous (human) Review and Immune Globulin Intravenous (human) Label ), REVLIMID (Unk) (View Revlimid Review and Revlimid Label ). Patient was hospitalized.

6881308-7 | Anaemia, Dizziness, Gastrointestinal Haemorrhage, Hypertrophic Cardiomyopathy, Hypotension
Adverse event was reported on Jul 20, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 3.5 Mg, Unk) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: UNITED STATES , 71 years of age, weighting 209.0 lb, After Velcade was administered, patient had the following side effects: anaemia, dizziness (What is dizziness?), gastrointestinal haemorrhage, hypertrophic cardiomyopathy, hypotension. During the same period patient was treated with ALKERAN (18 Mg, Qd) (View Alkeran Review and Alkeran Label ). Patient was hospitalized.

6881301-4 | Clostridium Difficile Colitis, Diarrhoea, Hypokalaemia, Orthostatic Hypotension
on Jul 20, 2010 Female patient from UNITED STATES , weighting 125.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), type 2 diabetes mellitus, hypothyroidism, orthostatic hypotension, hypercholesterolaemia and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: clostridium difficile colitis, diarrhoea, hypokalaemia, orthostatic hypotension. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with MELPHALAN (16 Mg, Cyclic) (View Melphalan Review and Melphalan Label ), PREDNISONE (100 Mg, Cyclic) (View Prednisone Review and Prednisone Label ), ZOMETA (View Zometa Review and Zometa Label ), METFORMIN HCL (500 Mg, Bid) (View Metformin Hcl Review and Metformin Hcl Label ), SYNTHROID (50 Ug, Qd) (View Synthroid Review and Synthroid Label ), FLORINEF (0.2 Mg, Qd) (View Florinef Review and Florinef Label ), SIMVASTATIN (40 Mg, Qd) (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6871305-X | Blood Phosphorus Decreased, Pneumonia
on Jul 15, 2010 Male patient from UNITED STATES , weighting 207.0 lb, was diagnosed with myelodysplastic syndrome and was treated with Velcade (View Usage). Patient had the following side effects: blood phosphorus decreased, pneumonia (What is pneumonia?). Velcade dosage: 1.3 Mg, Cyclic. During the same period patient was treated with LENALIDOMIDE (10 Mg, Cyclic) (View Lenalidomide Review and Lenalidomide Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), COUMADIN (View Coumadin Review and Coumadin Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6868608-1 | Abdominal Pain Upper, Adhesion
Patient was taking Velcade (View Usage). After Velcade was administered, patient had the following side effects: abdominal pain upper, adhesion (What is adhesion?) on Jul 21, 2010 from UNITED STATES Additional patient health information: Female patient , 65 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: . During the same period patient was treated with CYTOXAN (View Cytoxan Review and Cytoxan Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6865945-1 | Anaemia, Haemorrhoidal Haemorrhage, Thrombocytopenia
Adverse event was reported on Jul 06, 2010 by a Female patient taking Velcade (View Usage) (Dosage: 2.2 Mg, Cyclic, Intravenous) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: FRANCE , 75 years of age, Patient experienced the following unwanted or unexpected effects: anaemia, haemorrhoidal haemorrhage, thrombocytopenia. During the same period patient was treated with DEXAMETHASONE (20 Mg, Oral) (View Dexamethasone Review and Dexamethasone Label ), DASATINIB (DASATINIB) (140 Mg) (View Dasatinib (dasatinib) Review and Dasatinib (dasatinib) Label ). Patient was hospitalized.

6863363-3 | Osteonecrosis
on Jul 13, 2010 Male patient from UNITED STATES , 67 years of age, weighting 200.6 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient had the following side effects: osteonecrosis (What is osteonecrosis?). Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with REVLIMID (25 Mg, Cyclic) (View Revlimid Review and Revlimid Label ), DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), ASPIRIN (325 Mg, Qd) (View Aspirin Review and Aspirin Label ), ZOMETA (View Zometa Review and Zometa Label ).

6862965-8 | Clostridium Difficile Colitis, Hypokalaemia, Orthostatic Hypotension
on Jul 13, 2010 Female patient from UNITED STATES , weighting 125.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), type 2 diabetes mellitus, hypothyroidism, hypercholesterolaemia and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: clostridium difficile colitis, hypokalaemia, orthostatic hypotension. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with MELPHALAN (16 Mg, Cyclic) (View Melphalan Review and Melphalan Label ), PREDNISONE (100 Mg, Cyclic) (View Prednisone Review and Prednisone Label ), ZOMETA (View Zometa Review and Zometa Label ), METFORMIN (500 Mg, Qd) (View Metformin Review and Metformin Label ), SYNTHROID (50 Ug, Qd) (View Synthroid Review and Synthroid Label ), FLORINEF (0.1 Mg, Bid) (View Florinef Review and Florinef Label ), SIMVASTATIN (40 Mg, Qd) (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6862552-1 | Vitreous Haemorrhage
Patient was taking Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: vitreous haemorrhage on Jul 06, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 58 years of age, weighting 138.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), thrombosis prophylaxis and. Velcade dosage: 2.2 Mg, Intravenous. During the same period patient was treated with DOXORUBICIN HCL (60 Mg, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40 Mg, Oral) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), ENOXAPARIN SODIUM (40 Mg) (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ).

6861410-6 | Abdominal Pain, Anaphylactic Reaction, Bacillus Infection, Bacteraemia, Blood Calcium Abnormal, Bone Pain, Chills, Haemoglobin Decreased
Adverse event was reported on Jul 06, 2010 by a Female patient taking Velcade (View Usage) (Dosage: 1.3 Mg/m2, Interavenous) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 16 years of age, weighting 156.1 lb, Patient had the following side effects: abdominal pain (What is abdominal pain?), anaphylactic reaction, bacillus infection, bacteraemia, blood calcium abnormal, bone pain, chills, haemoglobin decreased. During the same period patient was treated with VINCRISTINE (2 Mg, Intravenous) (View Vincristine Review and Vincristine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DECADRON (9 Mg, Intravenous) (View Decadron Review and Decadron Label ), PEGASPARGASE (PEGASPARGASE) (Intramuscular) (View Pegaspargase (pegaspargase) Review and Pegaspargase (pegaspargase) Label ), CYTARABINE (70 Mg, Intrathecal) (View Cytarabine Review and Cytarabine Label ), DOXORUBICIN HCL (107 Mg, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6860410-X | Colitis, Neutrophil Count Decreased, White Blood Cell Count Decreased
on Jul 10, 2010 Male patient from UNITED STATES , 65 years of age, weighting 274.3 lb, was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: colitis, neutrophil count decreased, white blood cell count decreased. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with FLAVOPIRIDOL (75 Mg/m2, Cyclic) (View Flavopiridol Review and Flavopiridol Label ). Patient was hospitalized.

6857959-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Blood Urea Increased, Hepatic Function Abnormal, Herpes Zoster, Neoplasm Progression
on Jul 05, 2010 Male patient from JAPAN , 65 years of age, weighting 130.1 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, blood urea increased, hepatic function abnormal, herpes zoster, neoplasm progression. Velcade dosage: 1.5 Mg, Cyclic, Intravenous; 1.1 Mg, Cyclic, Intravenous. During the same period patient was treated with DEXAMETHASONE (20 Mg, Intravenous) (View Dexamethasone Review and Dexamethasone Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), COTRIM (View Cotrim Review and Cotrim Label ), CIPROFLOXACIN HCL (View Ciprofloxacin Hcl Review and Ciprofloxacin Hcl Label ), VASEN (VOGLIBOSE) (View Vasen (voglibose) Review and Vasen (voglibose) Label ), AMARYL (View Amaryl Review and Amaryl Label ), TAKEPRON (LANSOPRZOLE) (View Takepron (lansoprzole) Review and Takepron (lansoprzole) Label ).

6844918-9 |
Patient was taking Velcade (View Usage). on Jul 08, 2010 from UNITED STATES Additional patient health information: Male patient , 63 years of age, weighting 162.3 lb, was diagnosed with acute myeloid leukaemia and. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with DAUNORUBICIN HCL (60 Mg/m2, Cyclic) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (100 Mg/m2, Cyclic) (View Cytarabine Review and Cytarabine Label ), ROXANOL (View Roxanol Review and Roxanol Label ), XANAX (View Xanax Review and Xanax Label ), CLARITIN /00917501/ (View Claritin /00917501/ Review and Claritin /00917501/ Label ), PROZAC /00724401/ (View Prozac /00724401/ Review and Prozac /00724401/ Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ).

6840151-5 | Thrombosis
Adverse event was reported on Jul 07, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 1.0 Mg/m2, Unk) was diagnosed with multiple myeloma (What is multiple myeloma?), pain (What is pain?) and. Location: UNITED STATES , weighting 161.8 lb, After Velcade was administered, patient had the following side effects: thrombosis. During the same period patient was treated with DOXIL (30 Mg/m2, Unk) (View Doxil Review and Doxil Label ), DEXAMETHASONE ACETATE (20 Mg, Unk) (View Dexamethasone Acetate Review and Dexamethasone Acetate Label ), CYCLOPHOSPHAMIDE (750 Mg/m2, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ), FRAGMIN (Unk) (View Fragmin Review and Fragmin Label ), OXYCODONE HCL (Unk) (View Oxycodone Hcl Review and Oxycodone Hcl Label ), MIRALAX (Unk) (View Miralax Review and Miralax Label ), ZANTAC /00550802/ (150 Mg, Bid) (View Zantac /00550802/ Review and Zantac /00550802/ Label ), BACLOFEN (Unk) (View Baclofen Review and Baclofen Label ). Patient was hospitalized.

6837296-2 | Herpes Zoster, Optic Neuritis, Papilloedema
on Jun 23, 2010 Male patient from NETHERLANDS , 61 years of age, weighting 165.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: herpes zoster, optic neuritis, papilloedema. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with NEXIUM (View Nexium Review and Nexium Label ), SEKOKEEN /00376902/ (METOPROLOL TARTRATE) (View Sekokeen /00376902/ (metoprolol Tartrate) Review and Sekokeen /00376902/ (metoprolol Tartrate) Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), PAMIDRONIC ACID (PAMIDRONIC ACID) (View Pamidronic Acid (pamidronic Acid) Review and Pamidronic Acid (pamidronic Acid) Label ). Patient was hospitalized and became disabled.

6832305-9 | Small Intestine Carcinoma
on Jul 02, 2010 Female patient from UNITED STATES , 50 years of age, was diagnosed with small intestine carcinoma metastatic and was treated with Velcade (View Usage). Patient had the following side effects: small intestine carcinoma. Velcade dosage: . During the same period patient was treated with VORINOSTAT (View Vorinostat Review and Vorinostat Label ). Patient was hospitalized.

6829165-9 | Herpes Zoster, Optic Neuritis, Papilloedema
Patient was taking Velcade (View Usage). After Velcade was administered, patient had the following side effects: herpes zoster, optic neuritis, papilloedema on Jun 23, 2010 from NETHERLANDS Additional patient health information: Male patient , 61 years of age, weighting 165.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 1.3 Mg/m2, Cyclic;. During the same period patient was treated with NEXIUM (View Nexium Review and Nexium Label ), SELOKEEN (METOPROLOL TARTRATE) (View Selokeen (metoprolol Tartrate) Review and Selokeen (metoprolol Tartrate) Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), PAMIDRONIC ACID (View Pamidronic Acid Review and Pamidronic Acid Label ). Patient was hospitalized and became disabled.

6829164-7 | Disease Progression, Hypoaesthesia, Neuropathy Peripheral
Adverse event was reported on Jun 21, 2010 by a Female patient taking Velcade (View Usage) (Dosage: 1.30 Mg/m2, Intravenous) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: JAPAN , 74 years of age, Patient experienced the following unwanted or unexpected effects: disease progression, hypoaesthesia, neuropathy peripheral.

6818978-5 | Gastrointestinal Haemorrhage
on Jul 06, 2010 Male patient from POLAND , weighting 130.1 lb, was diagnosed with mantle cell lymphoma and was treated with Velcade (View Usage). Patient had the following side effects: gastrointestinal haemorrhage. Velcade dosage: Unk. During the same period patient was treated with PREDNISONE (165 Mg, Unk) (View Prednisone Review and Prednisone Label ).

6815508-9 | Blood Creatine Phosphokinase Increased, Dehydration, Pyrexia, Renal Failure Acute, Sepsis, Tumour Lysis Syndrome
on Jun 24, 2010 Male patient from UNITED STATES , 49 years of age, weighting 213.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: blood creatine phosphokinase increased, dehydration, pyrexia, renal failure acute, sepsis (What is sepsis?), tumour lysis syndrome. Velcade dosage: 2.7 Mg, Unk. During the same period patient was treated with ZOMETA (3.5 Mg, Q4weeks) (View Zometa Review and Zometa Label ). Patient was hospitalized.

6815445-X | Clostridial Infection, Decubitus Ulcer, Guillain-barre Syndrome, Mucocutaneous Rash, Neuropathy Peripheral, Neurotoxicity, Sepsis
Patient was taking Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: clostridial infection, decubitus ulcer, guillain-barre syndrome (What is guillain-barre syndrome?), mucocutaneous rash, neuropathy peripheral, neurotoxicity, sepsis (What is sepsis?) on Jun 24, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 103.0 lb, . Velcade dosage: 1.6 Mg/m2, Unk. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized and became disabled.

6815245-0 | Abdominal Distension, Alanine Aminotransferase Increased, Anaemia, Back Pain, Bacterial Infection, Blood Albumin Decreased, Blood Calcium Decreased, Blood Lactate Dehydrogenase Increased, Blood Potassium Increased
Adverse event was reported on Jun 18, 2010 by a Female patient taking Velcade (View Usage) (Dosage: 1.7 Mg, Intravenous) was diagnosed with multiple myeloma (What is multiple myeloma?), rheumatoid arthritis (What is rheumatoid arthritis?) and. Location: JAPAN , 63 years of age, weighting 92.59 lb, Patient had the following side effects: abdominal distension, alanine aminotransferase increased, anaemia, back pain (What is back pain?), bacterial infection (What is bacterial infection?), blood albumin decreased, blood calcium decreased, blood lactate dehydrogenase increased, blood potassium increased. During the same period patient was treated with DECADRON (20 Mg, Oral; 10 Mg, Oral) (View Decadron Review and Decadron Label ), DEXAMETHASONE (10 Mg, Oral) (View Dexamethasone Review and Dexamethasone Label ), DICLOFENAC SODIUM (75 Mg, Oral) (View Diclofenac Sodium Review and Diclofenac Sodium Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), ALENDRONATE SODIUM (View Alendronate Sodium Review and Alendronate Sodium Label ). Patient was hospitalized.

6812858-7 | Muscular Weakness
on Jun 22, 2010 Male patient from UNITED STATES , weighting 262.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: muscular weakness. Velcade dosage: Unk. During the same period patient was treated with DEXAMETHASONE (10 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), THALIDOMIDE (100 Mg, Cyclic) (View Thalidomide Review and Thalidomide Label ), ACETAMINOPHEN AND HYDROCODONE BITARTRATE (View Acetaminophen And Hydrocodone Bitartrate Review and Acetaminophen And Hydrocodone Bitartrate Label ), PERCOCET (View Percocet Review and Percocet Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), COREG (View Coreg Review and Coreg Label ), CLARITIN /00917501/ (View Claritin /00917501/ Review and Claritin /00917501/ Label ). Patient was hospitalized.

6811256-X | Dehydration, Diarrhoea, Urinary Tract Infection
on Jun 24, 2010 Female patient from UNITED STATES , weighting 124.1 lb, was diagnosed with renal cell carcinoma, hypothyroidism, herpes virus infection, appetite disorder, cardiovascular event prophylaxis and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, diarrhoea, urinary tract infection (What is urinary tract infection?). Velcade dosage: 1.8 Mg/m2, Cyclic. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg, Cyclic) (View Bevacizumab Review and Bevacizumab Label ), SYNTHROID (50 Ug, Qd) (View Synthroid Review and Synthroid Label ), ZOVIRAX /00587301/ (800 Mg, Qd) (View Zovirax /00587301/ Review and Zovirax /00587301/ Label ), MEGACE (40 Mg, Prn) (View Megace Review and Megace Label ), ASPIRIN (81 Mg, Qd) (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6811246-7 | Cardiac Failure, Hypophagia, Hypotension, Nausea, Restrictive Cardiomyopathy
Patient was taking Velcade (View Usage). Patient had the following side effects: cardiac failure, hypophagia, hypotension, nausea (What is nausea?), restrictive cardiomyopathy on Jun 23, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 144.8 lb, was diagnosed with amyloidosis, constipation (What is constipation?) and. Velcade dosage: 1.3 Mg/m2, Cyclic. During the same period patient was treated with DEXAMETHASONE (20 Mg, Cyclic) (View Dexamethasone Review and Dexamethasone Label ), MELPHALAN HYDROCHLORIDE (50 Mg/m2, Unk) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), DALTEPARIN SODIUM (Unk) (View Dalteparin Sodium Review and Dalteparin Sodium Label ), AMIODARONE (200 Mg, Qd) (View Amiodarone Review and Amiodarone Label ), METOPROLOL TARTRATE (12.5 Mg, Bid) (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ROSUVASTATIN (5 Mg, Qd) (View Rosuvastatin Review and Rosuvastatin Label ), OMEPRAZOLE (20 Mg, Qd) (View Omeprazole Review and Omeprazole Label ), POLYETHYLENE GLYCOL (17 G, Prn) (View Polyethylene Glycol Review and Polyethylene Glycol Label ). Patient was hospitalized.

6809834-7 | Blood Pressure Decreased, Cardiac Failure, Cardio-respiratory Arrest, Chest Pain, Diarrhoea, Disseminated Intravascular Coagulation, Dizziness, Ileus Paralytic, No Therapeutic Response
Adverse event was reported on Jun 17, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 1.6 Mg, Intravenous) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: JAPAN , 70 years of age, weighting 138.9 lb, After Velcade was administered, patient had the following side effects: blood pressure decreased, cardiac failure, cardio-respiratory arrest, chest pain (What is chest pain?), diarrhoea, disseminated intravascular coagulation, dizziness (What is dizziness?), ileus paralytic, no therapeutic response. During the same period patient was treated with DECADRON (16 Mg, Intravenous) (View Decadron Review and Decadron Label ), KYTRIL (View Kytril Review and Kytril Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), SEISHOKU (SODIUM CHLORIDE) (View Seishoku (sodium Chloride) Review and Seishoku (sodium Chloride) Label ), SODIUM BICARBONATE (View Sodium Bicarbonate Review and Sodium Bicarbonate Label ), ZOMETA (View Zometa Review and Zometa Label ), SOLDEM 3A (SODIUM LACTATE, POTASSIUM CHLORIDE, CARBOHYDRATES NOS, SODI (View Soldem 3a (sodium Lactate, Potassium Chloride, Carbohydrates Nos, Sodi Review and Soldem 3a (sodium Lactate, Potassium Chloride, Carbohydrates Nos, Sodi Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

6809578-1 | Erythema Multiforme, Herpes Simplex, Neutrophil Count Decreased, Pain, Platelet Count Decreased
on Jun 17, 2010 Female patient from JAPAN , 60 years of age, weighting 108.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: erythema multiforme, herpes simplex (What is herpes simplex?), neutrophil count decreased, pain (What is pain?), platelet count decreased. Velcade dosage: 1.60 Mg, Intravenous; 1.4 Mg, Intravenous; 1.4 Mg, Intravenous; 1.8 Mg, Intravenous. During the same period patient was treated with ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), RISEDRONATE SODIUM (View Risedronate Sodium Review and Risedronate Sodium Label ), CALCIUM LACTATE (CALCIUM LACTATE) (View Calcium Lactate (calcium Lactate) Review and Calcium Lactate (calcium Lactate) Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.

6800790-4 | Acute Myocardial Infarction, Altered State Of Consciousness, Apparent Life Threatening Event, Cerebral Infarction, Herpes Zoster, Hypokalaemia, Hyponatraemia, Metastases To Central Nervous System, Platelet Count Decreased
on Jun 16, 2010 Female patient from JAPAN , 76 years of age, weighting 154.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), renal impairment, herpes zoster, prophylaxis and was treated with Velcade (View Usage). Patient had the following side effects: acute myocardial infarction, altered state of consciousness, apparent life threatening event, cerebral infarction, herpes zoster, hypokalaemia, hyponatraemia, metastases to central nervous system, platelet count decreased. Velcade dosage: 1.8 Mg, Intravenous. During the same period patient was treated with DECADRON (20 Mg, Intravenous) (View Decadron Review and Decadron Label ), LASIX (40 Mg, Oral) (View Lasix Review and Lasix Label ), VALTREX (3g, Oral) (View Valtrex Review and Valtrex Label ), ITRACONAZOLE (200 Mg, Oral) (View Itraconazole Review and Itraconazole Label ), ETODOLAC (View Etodolac Review and Etodolac Label ), DUROTEP (FENTANYL) (View Durotep (fentanyl) Review and Durotep (fentanyl) Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ).

6795545-3 | Encephalopathy, Peripheral Sensory Neuropathy
Patient was taking Velcade (View Usage). After Velcade was administered, patient had the following side effects: encephalopathy, peripheral sensory neuropathy on Jun 14, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 122.4 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), transient ischaemic attack and. Velcade dosage: 1.3 Mg/m2, Unk. During the same period patient was treated with THALIDOMIDE (100 Mg, Unk) (View Thalidomide Review and Thalidomide Label ), DEXAMETHASONE (20 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), ASPIRIN (81 Mg, Unk) (View Aspirin Review and Aspirin Label ), XANAX (View Xanax Review and Xanax Label ), METHSCOPOLAMINE BROMIDE (View Methscopolamine Bromide Review and Methscopolamine Bromide Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), CLONIDINE (0.1 Mg, Prn) (View Clonidine Review and Clonidine Label ), COUMADIN (2.5 Mg, Unk) (View Coumadin Review and Coumadin Label ). Patient was hospitalized.

6794945-5 | Myelodysplastic Syndrome
Adverse event was reported on Jun 15, 2010 by a Female patient taking Velcade (View Usage) (Dosage: ) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , 57 years of age, weighting 198.9 lb, Patient experienced the following unwanted or unexpected effects: myelodysplastic syndrome. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), RITUXAN (View Rituxan Review and Rituxan Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ).

6791407-6 | Dialysis
on Jun 16, 2010 Male patient from UNITED STATES , weighting 175.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient had the following side effects: dialysis (What is dialysis?). Velcade dosage: 2.6 Mg, Cyclic.

6787382-0 | Atrial Fibrillation, Cardiac Failure Congestive, Diastolic Dysfunction, Epistaxis, Melaena, Pneumonia, Rectal Haemorrhage, Sepsis
on Jun 16, 2010 Female patient from UNITED STATES , 79 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), cardiac failure congestive, diastolic dysfunction, epistaxis, melaena, pneumonia (What is pneumonia?), rectal haemorrhage, sepsis (What is sepsis?). Velcade dosage: 2.3 Mg, Unk. Patient was hospitalized.

6786980-8 | Myelodysplastic Syndrome
Patient was taking Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: myelodysplastic syndrome on Jun 15, 2010 from UNITED STATES Additional patient health information: Female patient , 57 years of age, weighting 198.9 lb, was diagnosed with mantle cell lymphoma and. Velcade dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE ACETATE (View Dexamethasone Acetate Review and Dexamethasone Acetate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), RITUXAN (View Rituxan Review and Rituxan Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ).

6786974-2 | Pulmonary Embolism
Adverse event was reported on Jun 15, 2010 by a Male patient taking Velcade (View Usage) (Dosage: 0.7 Mg/m2, Cyclic) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 253.3 lb, Patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with VORINOSTAT (400 Mg, Cyclic) (View Vorinostat Review and Vorinostat Label ).

6786953-5 | Vitreous Haemorrhage
on Jun 08, 2010 Female patient from UNITED KINGDOM , 58 years of age, weighting 138.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?), thrombosis prophylaxis and was treated with Velcade (View Usage). After Velcade was administered, patient had the following side effects: vitreous haemorrhage. Velcade dosage: 2.2 Mg, Intravenous. During the same period patient was treated with DOXORUBICIN HCL (60 Mg, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40 Mg, Oral) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), ENOXAPARIN SODIUM (40 Mg) (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ).

6786946-8 | Cardiac Arrest, Diarrhoea, Hypokalaemia, Hypovolaemia, Neutropenic Sepsis, Vomiting
on Jun 08, 2010 Male patient from UNITED KINGDOM , 63 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Velcade (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), diarrhoea, hypokalaemia, hypovolaemia, neutropenic sepsis, vomiting. Velcade dosage: 2.5 Mg Cyclic, Intravenous. During the same period patient was treated with DOXORUBICIN HCL (18 Mg, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40 Mg, Cyclic, Oral) (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

6784990-8 | Dyspnoea, Fall, Neutropenic Sepsis, Thrombocytopenia
Patient was taking Velcade (View Usage). Patient had the following side effects: dyspnoea, fall (What is fall?), neutropenic sepsis, thrombocytopenia on Jun 08, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 58 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Velcade dosage: 2.3 Mg, Intravenous. During the same period patient was treated with DEXAMETHASONE TAB (40, Oral) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), DOXORUBICIN HCL (16, Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.